MarkLogic Stock

marklogic.comEnterprise SoftwareFounded: 1900Funding to Date: $187.49MM

MarkLogic is the developer of an operational and transactional Enterprise NoSQL database platform designed to empower customers to build next generation applications on a unified, 360-degree view of their data.

Enterprise Value (based on primary financings)

Register for Details

For more details on financing and valuation for MarkLogic, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

MarkLogic investors also invested in these private companies

Team

Management Team

Gary Bloom
Chief Executive Officer and President
Adrian Carr
Executive Vice President and Chief Operation Officer
Peter S Norman
Executive Vice President and Chief Financial Officer
Joe Pasqua
Executive Vice President, Products
David Ponzini
Executive Vice President, Corporate Development
Matt Allen
Vice President, Corporate Marketing
Robert Im
Vice President and General Counsel
Linda Kato
Vice President of People
David Gorbet
Senior Vice President, Engineering
Christopher Lindblad
Founder

Board Members

Gary Bloom
Christopher Lindblad
Tom Banahan
Tenaya Capital
Pat Grady
Sequoia Capital
Greg Santora

Other companies like MarkLogic in the Enterprise Software sector

Sector
Last Round Est. Valuation
$4.9B
Sector
Last Round Est. Valuation
$953.3MM
Sector
Last Round Est. Valuation
$6.84B
Sector
Last Round Est. Valuation
$2.71B
Sector
Last Round Est. Valuation
$327.9MM
Sector
Last Round Est. Valuation
$2.25B
Sector
Last Round Est. Valuation
$34.86B
Sector
Last Round Est. Valuation
$937.65MM

News

MarkLogic claims that the Data Hub Service provides a fast and cost-effective way for enterprises to integrate, store, analyze and secure mission-critical data in the cloud. None of this is ever easy, despite what company marketers will tell you.
The Document Databases market report correspondingly comprises a detailed market & vendor landscape aside from a SWOT analysis of the major players. Hence, the data provided is comprehensive, reliable, and the outcome of extensive research.
Biotech companies will open new doors to personalized drug development.